|
|
Post by mannmade on Jan 18, 2018 16:14:20 GMT -5
That was not my understanding but if I am wrong than my apologies.
|
|
|
|
Post by dreamboatcruise on Jan 18, 2018 16:15:15 GMT -5
As I recall Mnkd was once valued between $3B and $4B not that long ago, although it now seems like ages ago... I would be very happy with a 3B valuation within the next 12 to 18 months. With our current valuation at $298m as of the close today that would represent a 10 fold increase in pps share closed at $2.51 today or $25.10 at a $3B valuation. I would expect most of us would be very happy with that... GLTAL's!!! That's assuming zero further dilution to get us to that valuation. $3B would be on upper end of my range and I'd put time range of more like 24 to 36 months, but the no further dilution I would give near zero chance of being true. Would dilution cut that $25 to $20 or to $12.50, I couldn't predict at this point. |
|
|
|
Post by mannmade on Jan 18, 2018 16:16:17 GMT -5
I think, imho, the catalyst(s) could be any one or more of the following: 1. Announcement that mnkd met guidance (even if due to accounting change for scripts sent but not yet sold by retail)with new fuidance for next Q. 2. Filing of NDA for THP 3. RLS Update that is positive? 4. Expanded Insurance coverage 5. Guidance to break-even for Mnkd. 6. Oversees news about one or more distribution partners 7. One drop announcement for retail cash script program 8. Domestic partnership 9. Stat Study results (not likely until ADA, but might be used for discussions with potential partner) 10. Updates on various trials such as pediatric study enrollment 11. More specific information on how commercials are working with expectations for increased scripts. I am not saying any one of the above listed items will happen but they are all items mentioned by MC at the Fitzgerald Conference last September and since then as well. Therefore, some if not all should be making progress and could possibly provide the good news that is the impetus for a increase in pps.Sustained increase or one to trade around? I would think several or more on the list for sustained rally Was actually speaking to catalyst to get pps increase for cash raise. My belief is that only scripts and revenue raise pps for sustained growth. Until then we go up and down. However depending on the news events coupled with the cash raise we may not go as low as before. Just my opinion. |
|
|
|
Post by agedhippie on Jan 18, 2018 16:19:50 GMT -5
Sustained increase or one to trade around? I would think several or more on the list for sustained rally Was actually speaking to catalyst to get pps increase for cash raise. My belief is that only scripts and revenue raise pps for sustained growth. Until then we go up and down. However depending on the news events coupled with the cash raise we may not go as low as before. Just my opinion. You could add market manipulation  |
|
|
|
Post by peppy on Jan 18, 2018 17:22:04 GMT -5
Thank you deerfield? But seriously would it have worked without the label change as the catalyst to get share price up ? Say Df has to do this again soon what will the catalyst be? International partner? I think, imho, the catalyst(s) could be any one or more of the following: 1. Announcement that mnkd met guidance (even if due to accounting change for scripts sent but not yet sold by retail)with new fuidance for next Q. 2. Filing of NDA for THP 3. RLS Update that is positive? 4. Expanded Insurance coverage 5. Guidance to break-even for Mnkd. 6. Oversees news about one or more distribution partners 7. One drop announcement for retail cash script program 8. Domestic partnership 9. Stat Study results (not likely until ADA, but might be used for discussions with potential partner) 10. Updates on various trials such as pediatric study enrollment 11. More specific information on how commercials are working with expectations for increased scripts. I am not saying any one of the above listed items will happen but they are all items mentioned by MC at the Fitzgerald Conference last September and since then as well. Therefore, some if not all should be making progress and could possibly provide the good news that is the impetus for a increase in pps. earnings conference call is three weeks away. |
|
|
|
Post by sportsrancho on Jan 18, 2018 18:45:38 GMT -5
NASDAQ said earnings date is 3/9/2018. Has that changed?
|
|
|
|
Post by falconquest on Jan 18, 2018 20:11:21 GMT -5
What will propel the share price forward in a sustained manner is an increasing Afrezza script count and another FDA approved indication utilizing Technosphere technology. If Technosphere ever becomes the delivery vehicle of choice then the share price will see huge sustained growth. Thought we would be working on that by now.
|
|
|
|
Post by mnkdfann on Jan 18, 2018 20:47:41 GMT -5
NASDAQ said earnings date is 3/9/2018. Has that changed? When I look at the NASDAQ site, it tells me: "Our vendor, Zacks Investment Research, hasn't provided us with the upcoming earnings report date." www.nasdaq.com/earnings/report/mnkd |
|
|
|
Post by mnkdfann on Jan 18, 2018 20:52:30 GMT -5
Thank you deerfield? But seriously would it have worked without the label change as the catalyst to get share price up ? Say Df has to do this again soon what will the catalyst be? International partner? I think, imho, the catalyst(s) could be any one or more of the following: ... I am not saying any one of the above listed items will happen but they are all items mentioned by MC at the Fitzgerald Conference last September and since then as well. Therefore, some if not all should be making progress and could possibly provide the good news that is the impetus for a increase in pps. To increase the pps, MNKD should license Technosphere to Canopy Growth Corporation (WEED.TO) for $1 per year. Just to hitch its wagon to the cannabis train, and enjoy the ride. Heck, refund Canopy the $1 and throw in some shares if that is what it takes to get Canopy to go along. |
|
|
|
Post by derek2 on Jan 18, 2018 21:23:30 GMT -5
I think, imho, the catalyst(s) could be any one or more of the following: ... I am not saying any one of the above listed items will happen but they are all items mentioned by MC at the Fitzgerald Conference last September and since then as well. Therefore, some if not all should be making progress and could possibly provide the good news that is the impetus for a increase in pps. To increase the pps, MNKD should license Technosphere to Canopy Growth Corporation (WEED.TO) for $1 per year. Just to hitch its wagon to the cannabis train, and enjoy the ride. Heck, refund Canopy the $1 and throw in some shares if that is what it takes to get Canopy to go along. RLS has already partnered for THC / CBD delivery. Would be great to see some movement there. |
|
|
|
Post by cjm18 on Jan 18, 2018 21:27:03 GMT -5
Day traders expecting unfavorable PR tomorrow. Today’s daily short interest is through the roof.
|
|
|
|
Post by sportsrancho on Jan 18, 2018 21:28:37 GMT -5
NASDAQ said earnings date is 3/9/2018. Has that changed? When I look at the NASDAQ site, it tells me: "Our vendor, Zacks Investment Research, hasn't provided us with the upcoming earnings report date." www.nasdaq.com/earnings/report/mnkd Mine is from the CNBC real time app. imgur.com/a/o7NnP |
|
|
|
Post by mnkdfann on Jan 18, 2018 21:54:46 GMT -5
To increase the pps, MNKD should license Technosphere to Canopy Growth Corporation (WEED.TO) for $1 per year. Just to hitch its wagon to the cannabis train, and enjoy the ride. Heck, refund Canopy the $1 and throw in some shares if that is what it takes to get Canopy to go along. RLS has already partnered for THC / CBD delivery. Would be great to see some movement there. I know. But that's done little (or nothing) for us (in terms of the MNKD share price) so far. Unless RLS has world wide, or North American rights, why not hitch up with a cannabis company that is on fire now (e.g. Canopy) in order to promote interest in MNKD stock among the cannabis investing crowd. |
|
|
|
Post by mnkdfann on Jan 18, 2018 21:58:56 GMT -5
Well, you wrote 'NASDAQ said' earlier so I assumed you meant you actually looked at NASDAQ. The CNBC thing you sent me to now is obviously not updated accurately or regularly. The latest RECENT NEWS update on the page you directed me to is from 2016 and reads UPDATE1 Poor sales prompt Sanofi to pull plug on Mannkind inhaled insulin. |
|
|
|
Post by sportsrancho on Jan 18, 2018 22:12:29 GMT -5
Well, you wrote 'NASDAQ said' earlier so I assumed you meant you actually looked at NASDAQ. The CNBC thing you sent me to now is obviously not updated accurately or regularly. The latest RECENT NEWS update on the page you directed me to is from 2016 and reads UPDATE1 Poor sales prompt Sanofi to pull plug on Mannkind inhaled insulin. Yes I saw that you are right. It said it was from NASDAQ on the top of the page. But clearly even though they seem to be up-to-date on my other stocks they’re not up-to-date on MNKD. Here is another :https://imgur.com/a/BeQdo imgur.com/a/ozaGP |
|
